SlideShare a Scribd company logo
ANTIFUNGAL
DRUGS
CLASSIFICATION1. Antibiotics
A. Polyenes: Amphotericin B (AMB), Nystatin, Hamycin
B. Echinocandins:Caspofungin, Micafungin, Anidulafungin
C. Heterocyclic benzofuran: Griseofulvin
2. Antimetabolite Flucytosine (5-FC)
3. Azoles
A. Imidazoles
Topical: Clotrimazole, Econazole, Miconazole, Oxiconazole
Systemic: Ketoconazole
B. Triazoles: Fluconazole, (systemic) Itraconazole, Voriconazole, Posaconazole
4. Allylamine Terbinafine
5. topical agents Tolnaftate, Undecylenic acid, Benzoic acid,Quiniodochlor, Ciclopirox olamine,
Butenafine, Sod. thiosulfate.
Amphotericin B
,nystatin
Squalene
epoxide
14 a
demethylase
AMPHOTERICIN B
•Amphotericin B deoxycholate (C-AMB) nephrotoxicity
•Amphotericin B colloidal dispersion (ABCD) (not available in the U.S.)
Associated with acute reactions, including infusion-related fever and chills
•Liposomal amphotericin B (L-AMB)
•Amphotericin B lipid complex (ABLC)
• Invasive candidiasis
• Invasive aspergillosis
• Blastomycosis
• Histoplasmosis
• Coccidioidomycosis
Cryptococcosis
• Mucormycosis
• Sporotrichosis
• Empirical therapy in
immunocompromised host
ACUTE REACTION
•each infusion and chills, fever, aches and pain all over, nausea, vomiting and
dyspnoea lasting for 2–5 hour,
•When the reaction is severe—the dose should be increased gradually. Usually
the intensity of reaction decreases with continued medication.
•Injection of hydrocortisone 0.6 mg/ kg with the infusion may reduce the
intensity of reaction. Thrombophlebitis .
LONG-TERM TOXICITY
•Nephrotoxicity . dose-related. azotemia, reduced g.f.r., acidosis,
hypokalaemia and inability to concentrate urine.
• reverses slowly and often incompletely after stoppage of therapy. Anaemia:
develop progressing anaemia due to bone marrow depression. reversible.
•CNS toxicity: occurs only on intrathecal injection—headache, vomiting,
nerve palsies, etc.
FLUCYTOSINE
• Cryptococcosis (with amphotericin B)
Has broad activity but emergence of resistance limits usefulness as single-
agent therapy
• ↓ Dosage in patients with ↓ renal function
• Toxicity more frequent in patients with AIDS or azotemia
• depress bone marrow, leukopenia and thrombocytopenia
KETOCONAZOLE
•decreases androgen production from testes
•displaces testosterone from protein binding sites.
•Gynaecomastia, loss of hair and libido, and oligozoospermia
•Menstrual irregularities occur in some women due to suppression of estradiol
synthesis.
•dose-dependent decrease in serum hydrocortisone due to synthesis inhibition
has also been noted
•Orally administered KTZ is effective in dermatophytosis because it is
concentrated in the stratum corneum.
•It is an alternative to griseofulvin, but use is restricted due to potential adverse
effects. Used as a lotion or shampoo, KTZ is quite effective in seborrhoea of
scalp and dandruff.
•effective in monilial vaginitis, oral therapy (for 5–7 days) with KTZ is reserved
for recurrent cases or those not responding to topical agents.
•Administered orally, KTZ is effective in several types of systemic mycosis, but
triazoles, being more active with fewer side effects, have largely replaced it for
these indications.
•occasionally used in dermal leishmaniasis and in kala azar.
•High-dose used in Cushing’s syndrome to decrease corticosteroid production.
FLUCONAZOLE
• Invasive candidiasis
• Cryptococcosis
• Coccidioidomycosis
• Prophylaxis and empirical therapy in immunocompromised host
• Plasma concentrations are essentially the same whether the drug is given
orally or intravenously.
• Concentrations in CSF = 50%–90% of CP
• Inhibitor of CYP3A4 and CYP2C9
• Contraindicated during pregnancy
ITRACONAZOLE
• Invasive aspergillosis
• Blastomycosis
• Coccidioidomycosis
• Histoplasmosis
• Pseudallescheriasis
• Sporotrichosis
• Ringworm
• Onychomycosis
• Substrate for and potent inhibitor of CYP3A4
• Hepatotoxic
• Contraindicated in pregnancy and in women considering becoming pregnant
VORICONAZOLE
• Invasive aspergillosis
• Invasive candidiasis
• Pseudallescheriasis
• Oral bioavailability is 96%.
• Metabolized by CYPs 2C19/2C9 /3A4
• prolong the QTc interval
• Transient visual or auditory hallucinations are frequent after the first dose.
• Contraindicated in pregnancy
POSACONAZOLE
• Oropharyngeal candidiasis
• Prophylaxis in immunocompromised host against aspergillosis and
candidiasis
• Oral bioavailability enhanced by food
• Drugs that ↓ gastric acid ↓ posaconazole exposure
• Inhibits CYP3A4
• Can prolong the QTc interval
• headache and GI disorders
ISAVUCONAZOLE
• Invasive aspergillosis
• Mucormycosis
• Oral bioavailability is 98%.
• Substrate of and inhibitor of CYP3A4
• Does not appear to prolong QTc
ECHINOCANDINS
Caspofungin
• ↓ Dose in moderate hepatic impairment
Micafungin
• Reduction of micafungin dose in moderate hepatic failure is not required.
Anidulafungin
• No dose adjustment is needed for hepatic or renal failure
GRISEOFULVIN:
Inhibits microtubule function, disrupts assembly of the mitotic spindle
• Ringworm
• Onychomycosis
• Absorption is reduced by barbiturates
• Induces hepatic CYPs
ALLYLAMINES
Inhibit fungal squalene epoxidase and reduce ergosterol biosynthesis
Terbinafine
• Ringworm
• Onychomycosis
• Bioavailability is ∼ 40% due to first-pass metabolism in the liver.
• accumulates in skin, nails, and fat.
• initial t1/2 is ~ 12 h but extends to 200–400 h at steady state.
AGENTS ACTIVE AGAINST
MICROSPORIDIA AND PNEUMOCYSTIS
Albendazole
• Microsporidia infection
• Anthelmintic
• Inhibitor of α-tubulin polymerization
Fumagillin
• Microsporidia infection
• Used in immunocompromised individuals with intestinal microsporidiosis
due to Enterocytozoon bieneusi unresponsive to albendazole
• Not approved for human use in the U.S.
Pentamidine
• Pneumocystis jiroveci pneumonia
• Prophylaxis use to prevent PJP in at-risk individuals who cannot tolerate
trimethoprim-sulfamethoxazole
TOPICAL ANTIFUNGAL AGENTS
Topical Antifungal Agents -Nystatin
•Too toxic for systemic use
•Candidal infection of mucosa, skin, GIT, vagina
•Not absorbed so toxicity rare
•Bitter and foul taste
Topical Antifungal Agents- Azoles
•Clotrimazole, miconazole , ketoconazole,butaconazole, econazole ,
oxiconazole , sulconazole , terconazole, tioconazole , sertaconazole
•Superficial mycosis
•Tinea pedis , tinea corporis, tinea cruris, tinea versicolor, cutaneous ,
oropharyngeal , vulvoginal candidiasis
•Skin oitments, cream , lotion, vaginal cream, vaginal tablet
•Shampoo for seborrheic dermatitis
•Topical azoles +corticosteroid FDC
Topical Antifungal Agents-Tolnaftate
•tinea cruris and tinea corporis
•Because of poor penetrability, it is less effective in tinea pedis and other
hyperkeratinized lesions. ineffective in tinea capitis (involving scalp) and
tinea unguium (involving nails).
•Symptomatic relief occurs early, but if applications are discontinued before
the fungus bearing tissue is shed—relapses are common. Resistance does not
occur.
•Salicylic acid can aid tolnaftate by keratolytic action. Tolnaftate causes little
irritation, but is inferior in efficacy to imidazoles.not effective in candidiasis
or other types of superficial mycosis.
Topical Antifungal Agent-Ciclopirox
Olamine
•tinea infections, pityriasis versicolor and dermal candidiasis.
•High cure rates are reported. It penetrates superficial layers and reaches hair
roots but systemic absorption is negligible.
•Local tolerance without irritation is good. Sensitization occurs occasionally.
•Formulated as nail lacquer, it has been used in onychomycosis.
•Vaginal candidiasis can be treated by 1% ciclopirox vaginal cream
Topical Antifungal Agents-Allylamines
•Naftifine
1% cream, cutaneous dermatophytosis , candida infections
Effcetive as topical azoles
•Butenafine
1% cream ,superficial dermatophytosis,
•Terbenafine
1% cream tinea pedis , tinea cruris , tinea corporis , tinea versicolor
Topical Antifungal Agents-Benzoic Acid
•antifungal and antibacterial property in slightly acidic medium.
•Fungistatic action is weaker than tolnaftate; eradication of the fungus needs
prolonged application till infected keratin is totally shed.
• hyperkeratotic lesions, as Whitfield’s ointment: benzoic acid 5%, salicylic
acid 3%. its keratolytic action, helps to remove the infected tissue and
promotes the penetration of benzoic acid into the lesion.
•Irritation and burning sensation
THANK YOU

More Related Content

What's hot

Presentation clotrimazole drug
Presentation clotrimazole drugPresentation clotrimazole drug
Presentation clotrimazole drug
BUDDHABHUSHAN DONGRE
 
Clindamycin
ClindamycinClindamycin
Clindamycin
Dr Randy Chance
 
Clindamycin
ClindamycinClindamycin
Clindamycin
Shifa-At-Ara Zhizhi
 
Broad Spectrum Antibiotics
Broad Spectrum AntibioticsBroad Spectrum Antibiotics
Broad Spectrum Antibioticsmeducationdotnet
 
Anti fungals PHARMACOLOGY REVISION NOTES
Anti fungals PHARMACOLOGY REVISION NOTES Anti fungals PHARMACOLOGY REVISION NOTES
Anti fungals PHARMACOLOGY REVISION NOTES
TONY SCARIA
 
Lincosamides
LincosamidesLincosamides
Lincosamides
ANUSHA SHAJI
 
Antibiotics chloramphenicol and macrolides
Antibiotics   chloramphenicol and macrolidesAntibiotics   chloramphenicol and macrolides
Antibiotics chloramphenicol and macrolides
Grace Felciya
 
Aminoglycosides Antibiotic's
Aminoglycosides Antibiotic'sAminoglycosides Antibiotic's
Aminoglycosides Antibiotic's
Asraful Islam Rayhan
 
Tetracycline
TetracyclineTetracycline
Tetracycline
DrRiffat Farooqui
 
Drugs for Leishmaniasis & Filariasis
Drugs for Leishmaniasis & FilariasisDrugs for Leishmaniasis & Filariasis
Drugs for Leishmaniasis & Filariasis
BikashAdhikari26
 
Tetracyclines
Tetracyclines Tetracyclines
Tetracyclines
abdul waheed
 
Tetracyclines presentation
Tetracyclines presentationTetracyclines presentation
Tetracyclines presentation
ahmed khalifa
 
PHARMACOLOGY OF AMINOGLYCOSIDE ANTIBIOTICS
PHARMACOLOGY OF AMINOGLYCOSIDE ANTIBIOTICS  PHARMACOLOGY OF AMINOGLYCOSIDE ANTIBIOTICS
PHARMACOLOGY OF AMINOGLYCOSIDE ANTIBIOTICS
paramesh Researcher
 
Tetracyclines dr. johan pandian
Tetracyclines   dr. johan pandianTetracyclines   dr. johan pandian
Tetracyclines dr. johan pandian
Mahatma Gandhi Medical College & Hospital
 
Tetracyclines
TetracyclinesTetracyclines
Tetracyclines
bibi umeza
 

What's hot (17)

Clindamycin
ClindamycinClindamycin
Clindamycin
 
Presentation clotrimazole drug
Presentation clotrimazole drugPresentation clotrimazole drug
Presentation clotrimazole drug
 
Clindamycin
ClindamycinClindamycin
Clindamycin
 
Clindamycin
ClindamycinClindamycin
Clindamycin
 
Broad Spectrum Antibiotics
Broad Spectrum AntibioticsBroad Spectrum Antibiotics
Broad Spectrum Antibiotics
 
Anti fungals PHARMACOLOGY REVISION NOTES
Anti fungals PHARMACOLOGY REVISION NOTES Anti fungals PHARMACOLOGY REVISION NOTES
Anti fungals PHARMACOLOGY REVISION NOTES
 
Lincosamides
LincosamidesLincosamides
Lincosamides
 
Antibiotics chloramphenicol and macrolides
Antibiotics   chloramphenicol and macrolidesAntibiotics   chloramphenicol and macrolides
Antibiotics chloramphenicol and macrolides
 
Aminoglycosides Antibiotic's
Aminoglycosides Antibiotic'sAminoglycosides Antibiotic's
Aminoglycosides Antibiotic's
 
Tetracycline
TetracyclineTetracycline
Tetracycline
 
Drugs for Leishmaniasis & Filariasis
Drugs for Leishmaniasis & FilariasisDrugs for Leishmaniasis & Filariasis
Drugs for Leishmaniasis & Filariasis
 
Tetracyclines
Tetracyclines Tetracyclines
Tetracyclines
 
Tetracyclines presentation
Tetracyclines presentationTetracyclines presentation
Tetracyclines presentation
 
PHARMACOLOGY OF AMINOGLYCOSIDE ANTIBIOTICS
PHARMACOLOGY OF AMINOGLYCOSIDE ANTIBIOTICS  PHARMACOLOGY OF AMINOGLYCOSIDE ANTIBIOTICS
PHARMACOLOGY OF AMINOGLYCOSIDE ANTIBIOTICS
 
Tetracyclines dr. johan pandian
Tetracyclines   dr. johan pandianTetracyclines   dr. johan pandian
Tetracyclines dr. johan pandian
 
Tetracyclines
TetracyclinesTetracyclines
Tetracyclines
 
Aminoglycoside
AminoglycosideAminoglycoside
Aminoglycoside
 

Similar to Presentation1

Antifungals NURSING.pptx
Antifungals NURSING.pptxAntifungals NURSING.pptx
Antifungals NURSING.pptx
DrPruthaP
 
anti-fungal Drugs.pptx
anti-fungal Drugs.pptxanti-fungal Drugs.pptx
anti-fungal Drugs.pptx
DharaJoshi36
 
Antifungal agents
Antifungal agentsAntifungal agents
Antifungal agents
Chintan Doshi
 
Anti fungal agents
Anti fungal agentsAnti fungal agents
Anti fungal agents
Dr. Mohamed Maged Kharabish
 
Antifungal drugs
Antifungal drugs Antifungal drugs
Antifungal drugs
Naser Tadvi
 
Antifungals
AntifungalsAntifungals
Management of psoriasis.pptx (Recent advances)
Management of psoriasis.pptx (Recent advances)Management of psoriasis.pptx (Recent advances)
Management of psoriasis.pptx (Recent advances)
DR. MOHNISH SEKAR
 
Drugtherapy of Helminthiasis
Drugtherapy of HelminthiasisDrugtherapy of Helminthiasis
Drugtherapy of Helminthiasis
kartik1076
 
Introduction to antifungal drugs
Introduction to antifungal drugsIntroduction to antifungal drugs
Introduction to antifungal drugs
Subramani Parasuraman
 
Anti fungal agents
Anti  fungal agentsAnti  fungal agents
Anti fungal agents
JagirPatel3
 
Antifungals
AntifungalsAntifungals
Antifungals
mzabihi
 
Corticosteroids in ophthalmology
Corticosteroids in ophthalmologyCorticosteroids in ophthalmology
Corticosteroids in ophthalmologyPaavan Kalra
 
Antifungal drugs
Antifungal drugsAntifungal drugs
Antifungal drugs
narendrasinghmeena
 
Drugs for protozoan infections ( except malaria)
Drugs for protozoan infections ( except malaria) Drugs for protozoan infections ( except malaria)
Drugs for protozoan infections ( except malaria)
DrShrey Bhatia
 
Antifungal drugs
Antifungal drugsAntifungal drugs
Antifungal drugs
BikashAdhikari26
 
Anti-fungal drugs
Anti-fungal drugsAnti-fungal drugs
Anti-fungal drugs
Karun Kumar
 
anti mycobacterial and antileprotic drugs
anti mycobacterial and antileprotic drugsanti mycobacterial and antileprotic drugs
anti mycobacterial and antileprotic drugs
Sanju Kaladharan
 
Antitubercular drugs (ATT drugs)
Antitubercular drugs (ATT drugs)Antitubercular drugs (ATT drugs)
Antitubercular drugs (ATT drugs)
BrahmjotKaur11
 
Antifungal agents
Antifungal agentsAntifungal agents
Antifungal agents
Jitendra Chaturvedi
 

Similar to Presentation1 (20)

Antifungals NURSING.pptx
Antifungals NURSING.pptxAntifungals NURSING.pptx
Antifungals NURSING.pptx
 
anti-fungal Drugs.pptx
anti-fungal Drugs.pptxanti-fungal Drugs.pptx
anti-fungal Drugs.pptx
 
Antifungal agents
Antifungal agentsAntifungal agents
Antifungal agents
 
Antifungal drugs-Synthetic agents
Antifungal drugs-Synthetic agentsAntifungal drugs-Synthetic agents
Antifungal drugs-Synthetic agents
 
Anti fungal agents
Anti fungal agentsAnti fungal agents
Anti fungal agents
 
Antifungal drugs
Antifungal drugs Antifungal drugs
Antifungal drugs
 
Antifungals
AntifungalsAntifungals
Antifungals
 
Management of psoriasis.pptx (Recent advances)
Management of psoriasis.pptx (Recent advances)Management of psoriasis.pptx (Recent advances)
Management of psoriasis.pptx (Recent advances)
 
Drugtherapy of Helminthiasis
Drugtherapy of HelminthiasisDrugtherapy of Helminthiasis
Drugtherapy of Helminthiasis
 
Introduction to antifungal drugs
Introduction to antifungal drugsIntroduction to antifungal drugs
Introduction to antifungal drugs
 
Anti fungal agents
Anti  fungal agentsAnti  fungal agents
Anti fungal agents
 
Antifungals
AntifungalsAntifungals
Antifungals
 
Corticosteroids in ophthalmology
Corticosteroids in ophthalmologyCorticosteroids in ophthalmology
Corticosteroids in ophthalmology
 
Antifungal drugs
Antifungal drugsAntifungal drugs
Antifungal drugs
 
Drugs for protozoan infections ( except malaria)
Drugs for protozoan infections ( except malaria) Drugs for protozoan infections ( except malaria)
Drugs for protozoan infections ( except malaria)
 
Antifungal drugs
Antifungal drugsAntifungal drugs
Antifungal drugs
 
Anti-fungal drugs
Anti-fungal drugsAnti-fungal drugs
Anti-fungal drugs
 
anti mycobacterial and antileprotic drugs
anti mycobacterial and antileprotic drugsanti mycobacterial and antileprotic drugs
anti mycobacterial and antileprotic drugs
 
Antitubercular drugs (ATT drugs)
Antitubercular drugs (ATT drugs)Antitubercular drugs (ATT drugs)
Antitubercular drugs (ATT drugs)
 
Antifungal agents
Antifungal agentsAntifungal agents
Antifungal agents
 

More from Jyoti Sharma

phase 1 clinical trial
phase 1 clinical trialphase 1 clinical trial
phase 1 clinical trial
Jyoti Sharma
 
Anticholinergic drugs
Anticholinergic drugsAnticholinergic drugs
Anticholinergic drugs
Jyoti Sharma
 
Presentation1 final
Presentation1  finalPresentation1  final
Presentation1 final
Jyoti Sharma
 
4 generalanesthesia
4 generalanesthesia4 generalanesthesia
4 generalanesthesia
Jyoti Sharma
 
Broad spectrum antibiotics
Broad spectrum antibioticsBroad spectrum antibiotics
Broad spectrum antibiotics
Jyoti Sharma
 
Hypertension
HypertensionHypertension
Hypertension
Jyoti Sharma
 
Asthma
Asthma Asthma
Asthma
Jyoti Sharma
 
Melatonin and recent advances
Melatonin and recent advancesMelatonin and recent advances
Melatonin and recent advances
Jyoti Sharma
 
Antipsychotics and updates
Antipsychotics and updatesAntipsychotics and updates
Antipsychotics and updates
Jyoti Sharma
 

More from Jyoti Sharma (9)

phase 1 clinical trial
phase 1 clinical trialphase 1 clinical trial
phase 1 clinical trial
 
Anticholinergic drugs
Anticholinergic drugsAnticholinergic drugs
Anticholinergic drugs
 
Presentation1 final
Presentation1  finalPresentation1  final
Presentation1 final
 
4 generalanesthesia
4 generalanesthesia4 generalanesthesia
4 generalanesthesia
 
Broad spectrum antibiotics
Broad spectrum antibioticsBroad spectrum antibiotics
Broad spectrum antibiotics
 
Hypertension
HypertensionHypertension
Hypertension
 
Asthma
Asthma Asthma
Asthma
 
Melatonin and recent advances
Melatonin and recent advancesMelatonin and recent advances
Melatonin and recent advances
 
Antipsychotics and updates
Antipsychotics and updatesAntipsychotics and updates
Antipsychotics and updates
 

Recently uploaded

ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 

Recently uploaded (20)

ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 

Presentation1

  • 2. CLASSIFICATION1. Antibiotics A. Polyenes: Amphotericin B (AMB), Nystatin, Hamycin B. Echinocandins:Caspofungin, Micafungin, Anidulafungin C. Heterocyclic benzofuran: Griseofulvin 2. Antimetabolite Flucytosine (5-FC) 3. Azoles A. Imidazoles Topical: Clotrimazole, Econazole, Miconazole, Oxiconazole Systemic: Ketoconazole B. Triazoles: Fluconazole, (systemic) Itraconazole, Voriconazole, Posaconazole 4. Allylamine Terbinafine 5. topical agents Tolnaftate, Undecylenic acid, Benzoic acid,Quiniodochlor, Ciclopirox olamine, Butenafine, Sod. thiosulfate.
  • 5. •Amphotericin B deoxycholate (C-AMB) nephrotoxicity •Amphotericin B colloidal dispersion (ABCD) (not available in the U.S.) Associated with acute reactions, including infusion-related fever and chills •Liposomal amphotericin B (L-AMB) •Amphotericin B lipid complex (ABLC)
  • 6. • Invasive candidiasis • Invasive aspergillosis • Blastomycosis • Histoplasmosis • Coccidioidomycosis Cryptococcosis • Mucormycosis • Sporotrichosis • Empirical therapy in immunocompromised host
  • 7. ACUTE REACTION •each infusion and chills, fever, aches and pain all over, nausea, vomiting and dyspnoea lasting for 2–5 hour, •When the reaction is severe—the dose should be increased gradually. Usually the intensity of reaction decreases with continued medication. •Injection of hydrocortisone 0.6 mg/ kg with the infusion may reduce the intensity of reaction. Thrombophlebitis .
  • 8. LONG-TERM TOXICITY •Nephrotoxicity . dose-related. azotemia, reduced g.f.r., acidosis, hypokalaemia and inability to concentrate urine. • reverses slowly and often incompletely after stoppage of therapy. Anaemia: develop progressing anaemia due to bone marrow depression. reversible. •CNS toxicity: occurs only on intrathecal injection—headache, vomiting, nerve palsies, etc.
  • 9. FLUCYTOSINE • Cryptococcosis (with amphotericin B) Has broad activity but emergence of resistance limits usefulness as single- agent therapy • ↓ Dosage in patients with ↓ renal function • Toxicity more frequent in patients with AIDS or azotemia • depress bone marrow, leukopenia and thrombocytopenia
  • 10.
  • 11.
  • 12. KETOCONAZOLE •decreases androgen production from testes •displaces testosterone from protein binding sites. •Gynaecomastia, loss of hair and libido, and oligozoospermia •Menstrual irregularities occur in some women due to suppression of estradiol synthesis. •dose-dependent decrease in serum hydrocortisone due to synthesis inhibition has also been noted
  • 13. •Orally administered KTZ is effective in dermatophytosis because it is concentrated in the stratum corneum. •It is an alternative to griseofulvin, but use is restricted due to potential adverse effects. Used as a lotion or shampoo, KTZ is quite effective in seborrhoea of scalp and dandruff. •effective in monilial vaginitis, oral therapy (for 5–7 days) with KTZ is reserved for recurrent cases or those not responding to topical agents. •Administered orally, KTZ is effective in several types of systemic mycosis, but triazoles, being more active with fewer side effects, have largely replaced it for these indications. •occasionally used in dermal leishmaniasis and in kala azar. •High-dose used in Cushing’s syndrome to decrease corticosteroid production.
  • 14. FLUCONAZOLE • Invasive candidiasis • Cryptococcosis • Coccidioidomycosis • Prophylaxis and empirical therapy in immunocompromised host • Plasma concentrations are essentially the same whether the drug is given orally or intravenously. • Concentrations in CSF = 50%–90% of CP • Inhibitor of CYP3A4 and CYP2C9 • Contraindicated during pregnancy
  • 15. ITRACONAZOLE • Invasive aspergillosis • Blastomycosis • Coccidioidomycosis • Histoplasmosis • Pseudallescheriasis • Sporotrichosis • Ringworm • Onychomycosis • Substrate for and potent inhibitor of CYP3A4 • Hepatotoxic • Contraindicated in pregnancy and in women considering becoming pregnant
  • 16. VORICONAZOLE • Invasive aspergillosis • Invasive candidiasis • Pseudallescheriasis • Oral bioavailability is 96%. • Metabolized by CYPs 2C19/2C9 /3A4 • prolong the QTc interval • Transient visual or auditory hallucinations are frequent after the first dose. • Contraindicated in pregnancy
  • 17. POSACONAZOLE • Oropharyngeal candidiasis • Prophylaxis in immunocompromised host against aspergillosis and candidiasis • Oral bioavailability enhanced by food • Drugs that ↓ gastric acid ↓ posaconazole exposure • Inhibits CYP3A4 • Can prolong the QTc interval • headache and GI disorders
  • 18. ISAVUCONAZOLE • Invasive aspergillosis • Mucormycosis • Oral bioavailability is 98%. • Substrate of and inhibitor of CYP3A4 • Does not appear to prolong QTc
  • 19. ECHINOCANDINS Caspofungin • ↓ Dose in moderate hepatic impairment Micafungin • Reduction of micafungin dose in moderate hepatic failure is not required. Anidulafungin • No dose adjustment is needed for hepatic or renal failure
  • 20.
  • 21. GRISEOFULVIN: Inhibits microtubule function, disrupts assembly of the mitotic spindle • Ringworm • Onychomycosis • Absorption is reduced by barbiturates • Induces hepatic CYPs
  • 22. ALLYLAMINES Inhibit fungal squalene epoxidase and reduce ergosterol biosynthesis Terbinafine • Ringworm • Onychomycosis • Bioavailability is ∼ 40% due to first-pass metabolism in the liver. • accumulates in skin, nails, and fat. • initial t1/2 is ~ 12 h but extends to 200–400 h at steady state.
  • 23. AGENTS ACTIVE AGAINST MICROSPORIDIA AND PNEUMOCYSTIS Albendazole • Microsporidia infection • Anthelmintic • Inhibitor of α-tubulin polymerization
  • 24. Fumagillin • Microsporidia infection • Used in immunocompromised individuals with intestinal microsporidiosis due to Enterocytozoon bieneusi unresponsive to albendazole • Not approved for human use in the U.S.
  • 25. Pentamidine • Pneumocystis jiroveci pneumonia • Prophylaxis use to prevent PJP in at-risk individuals who cannot tolerate trimethoprim-sulfamethoxazole
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33. Topical Antifungal Agents -Nystatin •Too toxic for systemic use •Candidal infection of mucosa, skin, GIT, vagina •Not absorbed so toxicity rare •Bitter and foul taste
  • 34. Topical Antifungal Agents- Azoles •Clotrimazole, miconazole , ketoconazole,butaconazole, econazole , oxiconazole , sulconazole , terconazole, tioconazole , sertaconazole •Superficial mycosis •Tinea pedis , tinea corporis, tinea cruris, tinea versicolor, cutaneous , oropharyngeal , vulvoginal candidiasis •Skin oitments, cream , lotion, vaginal cream, vaginal tablet •Shampoo for seborrheic dermatitis •Topical azoles +corticosteroid FDC
  • 35. Topical Antifungal Agents-Tolnaftate •tinea cruris and tinea corporis •Because of poor penetrability, it is less effective in tinea pedis and other hyperkeratinized lesions. ineffective in tinea capitis (involving scalp) and tinea unguium (involving nails). •Symptomatic relief occurs early, but if applications are discontinued before the fungus bearing tissue is shed—relapses are common. Resistance does not occur. •Salicylic acid can aid tolnaftate by keratolytic action. Tolnaftate causes little irritation, but is inferior in efficacy to imidazoles.not effective in candidiasis or other types of superficial mycosis.
  • 36. Topical Antifungal Agent-Ciclopirox Olamine •tinea infections, pityriasis versicolor and dermal candidiasis. •High cure rates are reported. It penetrates superficial layers and reaches hair roots but systemic absorption is negligible. •Local tolerance without irritation is good. Sensitization occurs occasionally. •Formulated as nail lacquer, it has been used in onychomycosis. •Vaginal candidiasis can be treated by 1% ciclopirox vaginal cream
  • 37. Topical Antifungal Agents-Allylamines •Naftifine 1% cream, cutaneous dermatophytosis , candida infections Effcetive as topical azoles •Butenafine 1% cream ,superficial dermatophytosis, •Terbenafine 1% cream tinea pedis , tinea cruris , tinea corporis , tinea versicolor
  • 38. Topical Antifungal Agents-Benzoic Acid •antifungal and antibacterial property in slightly acidic medium. •Fungistatic action is weaker than tolnaftate; eradication of the fungus needs prolonged application till infected keratin is totally shed. • hyperkeratotic lesions, as Whitfield’s ointment: benzoic acid 5%, salicylic acid 3%. its keratolytic action, helps to remove the infected tissue and promotes the penetration of benzoic acid into the lesion. •Irritation and burning sensation

Editor's Notes

  1. Amphotericin B and other polyenes (e.g., nystatin) bind to ergosterol in fungal cell membranes and increase membrane permeability. imidazoles and triazoles (itraconazole, etc.) inhibit 14-α-sterol demethylase, prevent ergosterol synthesis, and lead to accumulation of toxic 14-α-methylsterols. allylamines (e.g., naftifine and terbinafine) inhibit squalene epoxidase and prevent ergosterol synthesis. echinocandins (e.g., caspofungin) inhibit the formation of glucans in the fungal cell wall. Metabolites of 5-fluorocytosine can disrupt fungal RNA and DNA synthesis. Griseofulvin inhibits microtubule assembly, thereby blocking fungal mitosis.
  2. The antifungal activity of amphotericin B depends on its capacity to bind ergosterol in the fungal cell membrane. B. Ergosterol, here depicted as a green rod, decorates both bilayers of the fungal membrane. C. Amphotericin B appears to form aggregates that sequester and effectively extract ergosterol from lipid bilayers, much like a selective sponge, disrupting membrane structure and resulting in fungal cell death.
  3. Associated with significant nephrotoxicity, including azotemia, renal tubular acidosis, and hypochromic, normocytic anemia C-AMB is tolerated by premature neonates much better than older children and adults; as a result, it remains an important part of the antifungal formulary in the critical care nursery. Infusion-related reactions typically decrease with subsequent infusions. While less toxic, the lipid formulations are much more costly than C-AMB, making them unavailable in many countries and dictating prudent use in the U.S. and other resource-rich areas.
  4. Invasive candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Unlike Candida infections in the mouth and throat (also called “thrush”) or vaginal “yeast infections,” invasive candidiasis is a serious infection that can affect the blood, heart, brain, eyes, bones, and other parts of the body.  Blastomyces dermatitidis HISTOPLASMA CAPSULATUM Coccidioides. immitis or Coccidioides posadasii fungi. Cryptococcus neoformans and Cryptococcus gattii. MUCORMYCESES / ZYGOMYCESES Mucor, Rhizopus, Absidia, and Cunninghamella genera also termed rose gardener's or rose handler's disease) is an infection caused by the fungus Sporothrix schenckii
  5. probably due to release of cytokines (IL, TNFα).
  6. Azotemia is an elevation of blood urea nitrogen (BUN) and serum creatinine levels. 
  7. All susceptible fungi are capable of deaminating flucytosine to 5FU, a potent antimetabolite that is used in cancer chemotherapy. Fluorouracil is metabolized first to 5FUMP) by the enzyme UPRTase. uracil phosphoribosyltransferase .5FUMP is then either incorporated into RNA (via synthesis of 5-fluorouridine triphosphate) or metabolized to 5FdUMP, a potent inhibitor of thymidylate synthase, ultimately inhibiting DNA synthesis. The selective action of flucytosine is due to the lack of cytosine deaminase in mammalian cells, which prevents metabolism to fluorouracil.
  8. A. Fungal ergosterol synthesis proceeds via a series of enzymic steps that include Erg11, a 14-α-sterol demethylase. The completed ergosterol is then inserted into both leaflets of the membrane bilayer. B. Imidazole and triazole antifungals inhibit the activity of 14-α-sterol demethylase, thereby reducing the biosynthesis of ergosterol and leading to the accumulation of 14-α-methylsterols. These methylsterols are toxic, disrupting the close packing of acyl chains of phospholipids, impairing the functions of certain membrane-bound enzyme systems, and thus inhibiting growth of the fungi.
  9. Pseudallescheriasis is a fungal infection caused by Pseudallescheria species, such as Pseudallescheria boydii Ringworm, also known as dermatophytosis, dermatophyte infection, or tinea, is a fungal infection of the skin. Onychomycosis, also known as tinea unguium, is a fungal infection of the nail. Symptoms may include white or yellow nail discoloration, thickening of the nail, and separation of the nail from the nail bed. Toenails or fingernails may be affected, but it is more common for toenails to be affected. Itraconazole is a triazole that lacks the corticosteroid suppression associated with ketoconazole while retaining most of ketoconazole’s pharmacological properties and extending the antifungal spectrum. Importantly, itraconazole has activity against Aspergillus spp. While imidazoles do not.
  10. • Invasive candidiasis • Empirical therapy in the immunocompromised host Prophylaxis in the immunocompromised host
  11. The strength of the fungal cell wall is maintained by fibrillar polysaccharides, largely β-1,3-glucan and chitin, which bind covalently to each other and to proteins. A glucan synthase complex in the plasma membrane catalyzes the synthesis of β-1,3-glucan; the glucan is extruded into the periplasm and incorporated into the cell wall. Echinocandins inhibit the activity of the glucan synthase complex, resulting in loss of the structural integrity of the cell wall. The Fks1p subunit of glucan synthase appears to be the target of echinocandins, and mutations in Fks1p cause resistance to echinocandins.
  12. Tinea capitis
  13. Tinea versicolor
  14. Tinea pedis
  15. Tinea corporis
  16. Tinea cruris
  17. tinea unguium